- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07836660
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
Study Overview
Status
Conditions
Detailed Description
This study is a randomized, double-blind, placebo-controlled Phase II study in participants with moderate-to-severe Sjögren's disease. Eligible participants will be randomized to receive IBI355 or placebo during the double-blind treatment period.
The study will evaluate the efficacy of IBI355 in reducing systemic disease activity and improving patient-reported symptoms and disease-related functional outcomes. Safety and tolerability will be assessed throughout the study. Pharmacokinetic, immunogenicity, pharmacodynamic, and other relevant clinical assessments will also be performed as specified in the protocol.
The results of this study are intended to characterize the efficacy and safety profile of IBI355 in participants with Sjögren's disease and to support its further clinical development.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: xiaoyan li
- Phone Number: 18756032014
- Email: xiaoyan.li@innoventbio.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230001
- The First Affiliated Hospital of University of Science and Technology of China
-
Principal Investigator:
- Xiaomei Li, M.D.
-
Contact:
- Xiaomei Li
- Phone Number: 13866795533
- Email: lixiaomei@fsmy@aliyun.com
-
Sub-Investigator:
- Zhen Tan, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 and ≤75 years.
- Diagnosis of Sjögren's syndrome per 2016 ACR/EULAR classification criteria.
- Duration of Sjögren's syndrome diagnosis ≤7.5 years.
- Serum anti-Ro/SSA (Ro60 and/or Ro52) positive.
- Stimulated whole saliva flow rate ≥0.05 mL/min at screening.
- Baseline ESSDAI score ≥5 in ≥1 of the following domains: systemic, lymphadenopathy, glandular, articular, cutaneous, renal, hematologic, biological.
- Stable background therapy (hydroxychloroquine ≤400 mg/day, methotrexate ≤25 mg/week, or azathioprine ≤150 mg/day) for ≥12 weeks with stable dose ≥8 weeks prior to randomization.
- Stable oral corticosteroid dose (≤10 mg/day prednisone equivalent) for ≥4 weeks prior to randomization.
Exclusion Criteria:
- Known hypersensitivity to IBI355 or its excipients.
- Pregnancy or breastfeeding.
- Uncontrolled interstitial lung disease (ILD) associated with Sjögren's syndrome (e.g., FVC <70% predicted, ClinESSDAI pulmonary domain indicating severe activity, or NYHA Class III/IV dyspnea).
- Active or untreated latent tuberculosis (IGRA-positive without ≥1 month prophylactic treatment).
- Chronic hepatitis B (HBsAg+), hepatitis C (HCV RNA+), HIV, or syphilis.
- Prior use of rituximab, other anti-CD20 agents, or other biologics targeting CD40/CD40L, BAFF/APRIL, or CTLA-4 within 6 months prior to randomization.
- Use of JAK/TYK inhibitors within 8 weeks prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part A: IBI355 group
IBI355,IV,corresponding dose regimen according to study cohort( Part A) . |
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design IBI355,IV,corresponding dose regimen according to study design |
|
Experimental: Part B: Telitacicept 160 mg group
Participants received telitacicept 160 mg SC QW from Week 0 to Week 24. Follow-up through Week 36 |
Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24). |
|
Experimental: Part A: Placebo group(IBI355-matched)
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design |
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design IBI355,IV,corresponding dose regimen according to study design |
|
Experimental: Part B: Placebo group (Telitacicept-matched)
Participants received matching placebo SC QW from Week 0 to Week 24. Follow-up through Week 36. |
Matching placebo of Talitacicept ,SC QW × 24 doses. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Time Frame: Baseline and Week 24
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement. |
Baseline and Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in ESSDAI Score at Weeks 12 and 48
Time Frame: Baseline to Weeks 12 and 48
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement. |
Baseline to Weeks 12 and 48
|
|
Change from Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 12, 24, and 48
Time Frame: Baseline to Weeks 12, 24, and 48
|
The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is a patient-reported measure assessing dryness, fatigue, and pain. Each domain is rated on a 0-to-10 numerical rating scale, and the total ESSPRI score is calculated as the mean of the three domain scores, ranging from 0 to 10. Higher scores indicate greater symptom severity. A decrease from baseline indicates improvement. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in Stimulated Salivary Flow (sSF) Rate at Weeks 12, 24, and 48
Time Frame: Baseline to Weeks 12, 24, and 48
|
Stimulated salivary flow rate will be measured according to the protocol-specified procedure. An increase from baseline indicates an improvement in stimulated salivary gland function. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in Schirmer Test at Week 48
Time Frame: Baseline to Week 48
|
The Schirmer test is used to assess tear production and is reported as the length of wetting of the test strip over 5 minutes, measured in millimeters (mm/5 min). Higher values indicate greater tear production. |
Baseline to Week 48
|
|
Change from Baseline in Sj?gren's Tool for Assessing Response (STAR) Score at Week 48
Time Frame: Baseline to Week 48
|
The Sj?gren's Tool for Assessing Response (STAR) is a composite assessment of treatment response in Sj?gren's disease incorporating systemic disease activity, patient-reported symptoms, and biological and glandular domains. Higher scores indicate a greater treatment response. |
Baseline to Week 48
|
|
Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Weeks 12, 24, and 48
Time Frame: Baseline to Weeks 12, 24, and 48
|
The FACIT-Fatigue scale is a 13-item patient-reported measure of fatigue. The total score ranges from 0 to 52, with higher scores indicating less fatigue and better functioning. An increase from baseline indicates improvement. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index Score at Weeks 12, 24, and 48
Time Frame: Baseline to Weeks 12, 24, and 48
|
The EQ-5D-5L is a standardized measure of health status assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity. Responses are converted to an EQ-5D-5L index score using the prespecified value set, with higher index scores indicating better health status. |
Baseline to Weeks 12, 24, and 48
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: From the first dose of study intervention through Week 48
|
The number and percentage of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) will be assessed throughout the study. |
From the first dose of study intervention through Week 48
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Mouth Diseases
- Stomatognathic Diseases
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Eye Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Lacrimal Apparatus Diseases
- Skin and Connective Tissue Diseases
- Sjogren's Syndrome
- telitacicept
Other Study ID Numbers
- CIBI355A201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.